Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Majalah Obat Tradisional Science and Technology Indonesia
Briliana, Malich Septi Diajeng
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Environmental Science Health Professions Materials Science & Nanotechnology Medicine & Pharmacology Physics Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Network Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular Mechanisms of Lansium parasiticum Bark Extract in Colon Cancer Treatment Mutiah, Roihatul; Briliana, Malich Septi Diajeng; Ahmad, Ananda Rizkia Azizah; Fauziyah, Begum; Janaloka, Nandana Adyuta; Suryadinata, Arief
Science and Technology Indonesia Vol. 9 No. 2 (2024): April
Publisher : Research Center of Inorganic Materials and Coordination Complexes, FMIPA Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26554/sti.2024.9.2.314-324

Abstract

Side effects and risk of resistance are common consequences of colon cancer treatment based on chemotherapy. The medicinal plant originating in Indonesia, Lansium parasiticum bark extract (LPBE), has not been studied much. The purpose of this study is to identify the compounds present in LPBE and explain how the molecular mechanisms of the composite inhibit colon cancer cells. LC-MS/MS Liquid Chromatography Tandem Mass Spectrophotometry has been used to identify compounds in LPBE. The ADMET program is used to determine absorption profiles and bioavailability per oral. The tissue pharmacology approach uses Cytoscape 3.9.1, GeneCards, Disgenet, STRING 2.0.0, SRplot, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway to predict the molecular anti-cancer mechanisms of these compounds. In vitro validation using PyRx Autodock Vina 9.0 and Biovia Discovery Studio with BAX (PDB ID:2YXJ), BCL2 (P DB ID:2W3L) and STAT3 receptors (PDB ID:6NJS). A total of 17 active compounds were identified through LC-MS/MS. The moronic acid compound showed the highest levels of 14.29% followed by 4-Morpholineacetic Acid 12.2% and ursolic aldehyde 8.37%. Pharmacological network analysis showed that the compounder works on the EGFR tyrosine kinase resistance path by targeting the BCL2, BAX, STAT3 genes. The results of the in silico validation support the results of tissue pharmacology findings. Ursolic aldehyde, and Moronic acid showed a higher affinity to the three receptors. Therefore, Lansium parasiticum bark extract (LPBE) is recommended for further study as a candidate anti-cancer drug both in vitro and in vivo.
Secondary Metabolites Analysis and Anti-Cancer Potential of Lansium parasiticum Extract Mutiah, Roihatul; Safina, Nilna Amalia Nur; Briliana, Malich Septi Diajeng
Majalah Obat Tradisional Vol 31, No 1 (2026)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/mot.99979

Abstract

Cancer is a non-communicable disease characterized by uncontrolled growth of malignant cells. The leaves and stems of Lansium parasiticum have been recognized for their potential as an anti-cancer agent. However, research reporting secondary metabolite profiles and anti-cancer activity in these plants remains limited. This study aimed to identify compounds, compare compound profiles, and predict the anti-cancer activity of secondary metabolites present in the leaves and stem bark of Lansium parasiticum. The secondary metabolite profile was analyzed using UPLC-MS/MS (Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry) chromatogram data interpretation, while the prediction of anticancer activity was made by referencing the Probability Activity value obtained through the PASS (Prediction of Activity Spectra for Substances) Server. The results revealed 24 bioactive compounds successfully identified from the Lansium parasiticum leaf extract, with Emindole Sb as the major compound comprising 19.3% of the total chromatographic area. Meanwhile, the analysis identified 23 bioactive compounds in the stem bark extract of Lansium parasiticum, with Moronic Acid as the major constituent, representing 14.29% of the total chromatographic area. The examination of the anticancer potential utilizing a probability activity method suggests that both the leaves and stem bark of Lansium parasiticum demonstrate antineoplastic, chemopreventive, and apoptosis-inducing activities.
Co-Authors Ahmad, Ananda Rizkia Azizah Arief Suryadinata Begum Fauziyah Janaloka, Nandana Adyuta Roihatul Mutiah Safina, Nilna Amalia Nur